Mesoporous silica nanoparticles (MSNs) represent a novel platform for drug delivery systems, reducing the cytotoxicity of the drug and being able to be functionalized to increase its effectiveness. Its activity is currently being investigated in numerous diseases, among which cancer stands out. Cancer is the main malignant neoplasm in women and the second worldwide, with more than 2.2 million new cases diagnosed in 2020. Of these, 15% belong to the triple negative subtype (TNBC), defined by the absence of receptors for both hormones and the epidermal growth factor HER2, which makes it difficult to develop treatments. In this work, the antitumor effect of MSNs loaded with a proapoptotic drug against TNBC has been confirmed by cell viability techniques and apoptosis assays, confirming the mechanism of action.